FY2025 · ended Dec 31, 2025 · Revenue $1.48B, -5.2% YoY · Filed Feb 25, 2026
Alkermes plc. (ALKS) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $1.5 billion and net income of $241.7 million. Free cash flow was $480.3 million. As of Sep 30, 2026 it held $787.6 million in cash and investments and $1.6 billion in total debt.
Revenue (TTM)
$1.75B
+15.3% vs year-ago TTM
Net income (TTM)
$-351,000
-100.1% vs year-ago TTM
Operating cash flow (TTM)
$242.99M
-55.1% vs year-ago TTM
Free cash flow (TTM)
$227.37M
-53.7% vs year-ago TTM
EPS (TTM)
$-0.00
-100.1% vs year-ago TTM
Dividend per share
None
Shares outstanding
166.65M
+2.5% vs prior year
Net cash
$-797.53M
as of Sep 30, 2026
Operating margin
3.7%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ALKS (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- Dublin 4, Ireland
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1520262
- Former names
- ANTLER SCIENCE TWO PLC (until Aug 5, 2011); Antler Science Two Ltd (until Aug 2, 2011)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $1.5B | $1.6B | $1.7B | $1.1B | $1.2B |
| Operating income | $254.0M | $420.6M | $414.1M | -$6.1M | $97.7M |
| Net income | $241.7M | $367.1M | $355.8M | -$158.3M | -$48.2M |
| Diluted EPS | $1.43 | $2.17 | $2.10 | -$0.97 | — |
| Operating cash flow | $520.8M | $439.1M | $401.4M | $21.0M | $101.7M |
| Free cash flow | $480.3M | $405.6M | $353.3M | -$17.2M | $73.7M |
| Total assets | $2.5B | $2.1B | $2.1B | $2.0B | $2.0B |
| Total liabilities | $667.7M | $590.6M | $933.5M | $920.2M | $911.9M |
| Stockholders' equity | $1.8B | $1.5B | $1.2B | $1.0B | $1.1B |
| Cash and investments | $588.4M | $824.8M | $813.4M | $740.1M | $765.7M |
| Total debt | $70.0M | $75.5M | $372.2M | $398.8M | $416.2M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 3, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 3, 2026 | Nov 3, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 21, 2026 | Sep 21, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Sep 16, 2026 | Sep 14, 2026 |
| 8-K |
Current report
Material agreement
|
Aug 12, 2026 | Aug 12, 2026 |
| 8-K/A |
Amended current report
Officer or director change
|
Aug 3, 2026 | Feb 24, 2026 |
All 1000 Alkermes plc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.